Joshua Michael Thurman
Physician at Red Fox Ln, Englewood, CO
License number
Colorado 39064
Issued Date
Sep 14, 2000
Renew Date
May 1, 2015
Expiration Date
Apr 30, 2017
Type
Physician
Address
Address
2 Red Fox Ln, Englewood, CO 80111
Personal information
See more information about Joshua Michael Thurman at radaris.comName
Address
Phone
2 Red Fox Ln, Greenwood Village, CO 80111
4200 9Th Ave, Denver, CO 80220
4200 9Th Ave, Denver, CO 80220
2 Red Fox Ln, Greenwood Village, CO 80111
1885 Logan St, Denver, CO 80210
Professional information
See more information about Joshua Michael Thurman at trustoria.com
Inhibition Of Factor B And The Alternative Complement Pathway For Treatment Of Traumatic Brain Injury And Related Conditions
Inhibition Of Factor B And The Alternative Complement Pathway For Treatment Of Traumatic Brain Injury And Related Conditions
US Patent:
2006029, Dec 28, 2006
Filed:
May 26, 2006
Appl. No.:
11/441828
Inventors:
Vernon Holers - Denver CO, US
Joshua Thurman - Greenwood Village CO, US
Stephen Tomlinson - Mount Pleasant SC, US
Philip Stahel - Denver CO, US
Joshua Thurman - Greenwood Village CO, US
Stephen Tomlinson - Mount Pleasant SC, US
Philip Stahel - Denver CO, US
Assignee:
The Regents of the University of Colorado - Boulder CO
MUSC Foundation for Research Development - Charleston SC
MUSC Foundation for Research Development - Charleston SC
International Classification:
A61K 39/395
US Classification:
424144100
Abstract:
Disclosed is the use of agents and compositions that selectively inhibit the alternative complement pathway for the inhibiting or treating physiological damage resulting from traumatic brain injury (TBI), spinal cord injury (SCI), or related conditions. Preferred reagents for use in inhibition of damage resulting from TBI or SCI include those that inhibit factor B, with anti-factor B antibodies representing a particularly preferred agent.
Antibodies To The C3D Fragment Of Complement Component 3
Antibodies To The C3D Fragment Of Complement Component 3
US Patent:
2013012, May 23, 2013
Filed:
Jun 22, 2011
Appl. No.:
13/805522
Inventors:
V. Michael Holers - Denver CO, US
Joshua M. Thurman - Greenwood Village CO, US
Liudmila Kulik - Aurora CO, US
Joshua M. Thurman - Greenwood Village CO, US
Liudmila Kulik - Aurora CO, US
Assignee:
The Regents of the University of Colorado, a Body Corporate - Denver CO
International Classification:
C07K 16/18
US Classification:
4241341, 5303898, 5303873, 5303882, 435332, 536 2353, 4353201, 435 696, 4241721, 435328, 4352523, 4352542, 435419, 43525233, 43525421, 43525423
Abstract:
The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.
Inhibition Of Factor B, The Alternative Complement Pathway And Methods Related Thereto
Inhibition Of Factor B, The Alternative Complement Pathway And Methods Related Thereto
US Patent:
2008007, Mar 27, 2008
Filed:
Aug 3, 2007
Appl. No.:
11/888997
Inventors:
Vernon Holers - Denver CO, US
Joshua Thurman - Greenwood Village CO, US
Christian Taube - Denver CO, US
Erwin Gelfand - Englewood CO, US
Gary Gilkeson - Charleston SC, US
Joshua Thurman - Greenwood Village CO, US
Christian Taube - Denver CO, US
Erwin Gelfand - Englewood CO, US
Gary Gilkeson - Charleston SC, US
International Classification:
C07K 16/46, A61K 39/395, A61P 11/06
US Classification:
424134100, 530391100
Abstract:
Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
Inhibition Of Factor B, The Alternative Complement Pathway And Methods Related Thereto
Inhibition Of Factor B, The Alternative Complement Pathway And Methods Related Thereto
US Patent:
2008010, May 1, 2008
Filed:
Aug 22, 2007
Appl. No.:
11/843617
Inventors:
V. Holers - Denver CO, US
Joshua Thurman - Greenwood Village CO, US
Christian Taube - Denver CO, US
Erwin Gelfand - Englewood CO, US
Gary Gilkeson - Charleston SC, US
Joshua Thurman - Greenwood Village CO, US
Christian Taube - Denver CO, US
Erwin Gelfand - Englewood CO, US
Gary Gilkeson - Charleston SC, US
International Classification:
A61K 9/14, A61K 39/395, A61P 11/02
US Classification:
424046000, 424130100
Abstract:
Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
Modulating The Alternative Complement Pathway
Modulating The Alternative Complement Pathway
US Patent:
2011022, Sep 22, 2011
Filed:
Sep 22, 2009
Appl. No.:
13/120125
Inventors:
Joshua M. Thurman - Greenwood Village CO, US
V. Michael Holers - Denver CO, US
V. Michael Holers - Denver CO, US
Assignee:
The Regents of the University of Colorado, a body corporate - Denver CO
International Classification:
A61K 39/395, A61P 43/00
US Classification:
4241781
Abstract:
Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins.
Non-Invasive Detection Of Complement-Mediated Inflammation Using Cr2-Targeted Nanoparticles
Non-Invasive Detection Of Complement-Mediated Inflammation Using Cr2-Targeted Nanoparticles
US Patent:
2011028, Nov 24, 2011
Filed:
Feb 4, 2010
Appl. No.:
13/148028
Inventors:
Joshua M. Thurman - Greenwood Village CO, US
Natalie Serkova - Denver CO, US
Conrad Stoldt - Denver CO, US
Brian Larsen - Denver CO, US
Natalie Serkova - Denver CO, US
Conrad Stoldt - Denver CO, US
Brian Larsen - Denver CO, US
Assignee:
The Regents of the University of Colorado - Denver CO
International Classification:
A61K 49/16, A61P 37/00, A61K 49/08
US Classification:
424 9323, 424 932
Abstract:
Methods of non-invasive imaging of complement-mediated inflammation are provided. Compositions including CR-targeted ultrasmall superparamagnetic nanoparticles or aggregates thereof for use with those methods are also provided.
Inhibition Of Factor B, The Alternative Complement Pathway And Methods Related Thereto
Inhibition Of Factor B, The Alternative Complement Pathway And Methods Related Thereto
US Patent:
2005026, Nov 24, 2005
Filed:
Feb 10, 2005
Appl. No.:
11/057047
Inventors:
Vernon Holers - Denver CO, US
Joshua Thurman - Greenwood Village CO, US
Christian Taube - Denver CO, US
Erwin Gelfand - Englewood CO, US
Gary Gilkeson - Charleston SC, US
Joshua Thurman - Greenwood Village CO, US
Christian Taube - Denver CO, US
Erwin Gelfand - Englewood CO, US
Gary Gilkeson - Charleston SC, US
Assignee:
The Regents of the University of Colorado - Boulder CO
National Jewish Medical and Research Center - Denver CO
MUSC Foundation for Research Development - Charleston SC
National Jewish Medical and Research Center - Denver CO
MUSC Foundation for Research Development - Charleston SC
International Classification:
A61K039/395, C07K016/28, C12P021/06, C12N015/09, C12N005/06
US Classification:
424144100, 530388220, 435069100, 435334000, 435320100
Abstract:
Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.